5/17/2022  4:25:10 PM Chg. +0.052 Volume Bid4:33:49 PM Ask4:25:10 PM Market Capitalization Dividend Y. P/E Ratio
1.070EUR +5.11% 19,726
Turnover: 21,166.318
1.022Bid Size: 4,037 1.070Ask Size: 3,406 72.91 mill.EUR 0.00% -

Business description

PAION AG is a publicly listed Specialty Pharmaceutical Company headquartered in Aachen (Germany) with further sites in Cambridge (United Kingdom) and New Jersey (USA). PAION's lead substance, Remimazolam, is an intravenous ultra-short-acting anesthetic that is currently in Phase III clinical development for procedural sedation and general anesthesia. Remimazolam has been investigated in more than 1,000 patients worldwide. Remimazolam is designed to complement and improve currently available treatment options for patients requiring sedation and anesthesia. PAION is focusing its clinical development activities on Remimazolam and has initiated pre-commercial activities according to PAION's vision to become an acknowledged “PAIONeer” in sedation and anesthesia.
 

Management board & Supervisory board

CEO
Dr. James Phillips
Management board
Abdelghani Omari (bis 1.06.2022), Sebastian Werner (ab 1.06.2022)
Supervisory board
Dr. Jörg Spiekerkötter, Dr. Karin Louise Dorrepaal, Dr. Chris Tanner, Dr. Dr. Irina Antonijevic, Dr. Markus Leyck Dieken
 

Company data

Name: PAION AG
Address: Heussstraße 25,D-52078 Aachen
Phone: +49-241-4453-0
Fax: +49-241-4453-100
E-mail: info@paion.de
Internet: www.paion.de/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 88.12%
IPO date: 2/10/2005

Investor relations

Name: Ralf Penner
IR phone: +49-241-4453-152
IR Fax: +49-241-4453-523
IR e-mail: investor.relations@paion.com

Company calendar

CW 21 | 5/18/2022 Interim Report 1st Quarter/3 Months
CW 22 | 5/25/2022 General Shareholder Meeting
CW 35 | 8/24/2022 Interim Report 2nd Quarter/6 Months
CW 47 | 11/16/2022 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
88.12%
Granell Strategic Investment Fund Limited
 
9.09%
TIAA-CREF Investment Management, LLC
 
2.79%